神奈川県川崎市宮前区菅生2-16-1
聖マリアンナ医科大学病院 腫瘍内科

業績・書籍紹介

書籍

チャートでわかる! がん化学療法のリアル
1. チャートでわかる! がん化学療法のリアル
  • 聖マリアンナ医科大学病院腫瘍センター

ご購入はこちら

学会発表(国内学会)

2022年度
2022.09 第76回日本食道学会学術集会
  • 食道扁平上皮癌・胃食道接合部癌におけるctDNAを用いた治療戦略
    Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Kumiko Umemoto, Naoki Izawa, Takashi Ogura, Yu Sunakawa.
2021年度
2021.05 第43回日本癌局所療法研究会
  • 切除不能胃癌に対してSP療法後にcomversion surgery を施行し、長期生存が得られた1例
    高城伸平, 民上真也, 天野優希, 亀井奈津子, 嶋田仁, 榎本武治, 伊澤直樹, 津田亨志, 砂川優, 有泉泰, 大坪毅人.
2021.05 第62回日本神経学会学術大会
  • 免疫チェックポイント阻害薬による中枢神経領域の免疫関連有害事象に関する検討.
    鏑木真弓, 水上平祐, 松本博文, 菱田吉明, 清水紗智, 緒方聖友, 韓蔚, 井澤直樹, 砂川優, 白石眞, 山野嘉久.
2021.05 第6回日本がんサポーティブケア学会学術集会
  • The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer.
    Hiroyuki Takeda, Shigenori Kadowaki, Takeshi Kajiwara, Keiko Minashi, Naoki Izawa, Kei Muro, Tomohiro Nishina, Shuichi Hironaka, Takeharu Yamanaka, Takako Eguchi Nakajima.
  • 免疫チェックポイント阻害薬の免疫関連有害事象に対する治療前の抗体検査の意義.
    大貫理沙, 伊澤直樹, 濱地広毅, 塩川尚恵, 森川慶, 佐治久, 大橋洋之, 春日井滋, 早川望, 大原樹, 水上拓郎, 田中 恒明, 砂川優.
2021.06 第27回日本遺伝性腫瘍学会学術集会
  • 当院におけるがん遺伝子パネル検査の二次的所見に関する検討.
    本吉愛, 右田王介, 小澤南, 高橋由妃, 杉下陽堂, 久我亜沙美, 大原樹, 古屋直樹, 小島康幸, 大橋洋之, 山本博幸, 井本清美, 砂川優, 山野嘉久, 津川浩一郎.
2021.09 第80回日本癌学会学術総会
  • 胃癌における腸内細菌ゲノム情報と患者背景の関係:DELIVER 試験.
    砂川 優, 的場 亮, 佐藤 慶治, 川上 尚人, 室 圭, 中島 貴子, 市川 度.
2021.09 第52回日本膵臓学会大会
  • 進行膵癌におけるリキッドバイオプシーと、KRAS野生型膵癌の治療開発に関する取り組み.
    梅本久美子、森実千種、中村能章、池田公史.
  • Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions.
    Kumiko Umemoto, Ernesto Wasserman.
2021.10 第59回日本癌治療学会学術集会
  • がん遺伝子パネル検査に基づいた治療提案と治療到達性.
    井本清美, 砂川 優, 武田弘幸, 大原 樹, 小島康幸, 古屋直樹, 大橋洋之, 山本博幸, 小池淳樹, 大川 千絵, 島田 直樹, 本吉 愛, 佐藤知雄, 谷嶋成樹, 山野嘉久.
  • Genomic factors of gut microbiome associated with patient characteristics in gastric cancer: from the DELIVER trial (JACCRO GC-08).
    Yu Sunakawa, Ryo Matoba, Yoshiharu Sato, Toshizo Takayama, Takeharu Imai, Naotoshi Sugimoto, Kou Miura, Satoshi Yuki, Yoshiaki Shindo, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.
2021.11 第62回日本肺癌学会学術集会
  • Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions.
    Alison M. Schram, Eileen Mary O’Reilly, Grainne M. O’Kane, Koichi Goto, Dong-Wan Kim, Cindy Neuzillet, Patricia Martin-Romano, Michaël Duruisseaux, Misako Nagasaka, Jordi Rodon, Benjamin Adam Weinberg, Kumiko Umemoto, Sai-Hong Ignatius Ou, Teresa Macarulla, Christelle De La Fouchardiere, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Alexander E. Drilon.
2021.11 厚生労働省「治療と仕事の両立支援」オンラインシンポジウム
  • 聖マリアンナ医科大学病院における両立支援相談体制の構築と進捗. 厚生労働省「治療と仕事の両立支援」オンラインシンポジウム
    山野嘉久, 長谷川大輔, 萩原悠太, 山徳雅人, 桑島則夫, 杉浦貴子, 伊澤直樹, 梶ヶ谷和子, 高田礼子.
2022.02 第19回日本臨床腫瘍学会学術集会
  • 遠隔医療を用いた治験プレスクリーニング検査の実装
    梅本久美子、砂川優、岩見さゆり、小林奈穂、松本生、斉藤修平、原聖吾.
  • Evaluation of annotations for cancer gene panel testing using a genome-guided syste.m
    Yu Sunakawa, Peter Koch, Hiroyuki Yamamoto, Ai Motoyoshi, Kiyomi Imoto, Martin Maerz, and Yoshihisa Yamano.
2022.03 第94回日本胃癌学会総会
  • A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09)
    “Yoshio Nagahisa, Naoki Izawa, Takashi Mine, Masahiro Goto, Hitoshi Fujii, Yosuke Kito, Ryohei Kawabata, Masato Nakamura, Mizutomo Azuma, Akihito Tsuji, Mitsugu Kochi, Takao Takahashi, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa, Masashi Fujii.
2020年度
2020.06 第24回腸内細菌学会学術集会(誌上開催)
  • 胃がん患者を対象とした腸内細菌叢の大規模臨床研究における採便に関するアンケート調査
    砂川優,的場亮,佐藤慶治,西山光恵,森原元彦,寺内淳,市川度,藤井雅志
2020.08 JASCC 緩和・支持・心のケア 合同学術大会
  • 「がんと診断されたときからの緩和ケア」の推進に関わる厚生労働行政への提言の策定
    釆野 優, 堀江 良樹, 森田 達也, 内藤 明美, 小山田 隼佑, 陶山 久司, 小島 康幸, 野里 洵子, 森 雅紀, 中島 貴子, 清水 千佳子, 恒藤 暁, 武藤 学
  • がん診断時からの緩和ケアを提供するための患者のアンメットニーズに関する研究
    内藤 明美, 釆野 優, 森田 達也, 堀江 良樹, 小山田 隼佑, 野里 洵子, 小島 康7, 陶山 久司, 森 雅紀, 中島 貴子, 清水 千佳子, 恒藤 暁, 武藤 学
2020.08 第106回日本消化器病学会総会
  • 血管新生阻害薬による化学療法中に下腸間膜動静脈瘻を合併した大腸癌症例
    土井綾子, 近江亮介, 梅本久美子, 新井裕之, 伊澤直樹, 小倉孝氏, 津田享志, 中島貴子
2020.11 第58回日本癌治療学会学術集会
  • 高齢者胃癌に対する治療の工夫
    Doi Ayako, Takeda Hiroyuki, Umemoto Kumiko, Arai Hiroyuki, Horie Yoshiki, Mizukami Takuro, Izawa Naoki, Ogura Takashi, Oguri Tomoyo, Sunakawa Yu.
  • Multi-gene panel testing in patients with gastro-intestinal cancers: A retrospective study.
    Takeda Hiroyuki, Imoto Kiyomi, Umemoto Kumiko, Doi Ayako, Arai Hiroyuki, Horie Yoshiki, Mizukami Takuro, Izawa Naoki, Ogura Takashi, Oguri Tomoyo, Sunakawa Yu.
2020.11 第17回 DIA日本年会2020
  • Practical situations of the clinical trial using digital scales and devices.
    水上 拓郎
2021.02 第18回日本臨床腫瘍学会学術集会
  • Anti-VEGF inhibitors and Renal Safety in Onco-Nephrology consortium -Urinary Protein/Creatinine ratio [VERSiON UP study].
    M. Nakamura, T. Funakoshi, S. Kataoka, T. Horimatsu, Y. Nishikawa, T. Matsubara, T. Mizukami, T. Goto, K. Tsuchihashi, E. Baba, T. Tsumura, Y. Mihara, T. Hamaguchi, M. Yanagita, M. Muto.
  • 進行固形がん患者における免疫チェックポイント阻害薬導入前の抗体検査と免疫関連有害事象との関連性
    塩川 尚恵、伊澤 直樹、森川 慶、大橋 洋之、早川 望、春日井 滋、武田 弘幸、梅本 久美子、新井 裕之、土井 綾子、 堀江 良樹、平川 麻美、水上 拓郎、小栗 知世、小倉 孝氏、田中 恒明、砂川 優
  • Gene profiling of circulating tumor DNA (ctDNA) in RAS wild-type mCRC patients who are refractory to anti-EGFR antibody.
    Naoki Izawa, Kazuto Nishio, Toshiki Masuishi, Naoki Takahashi, Hirokazu Shoji, Yoshiyuki Yamamoto, Toshihiko Matsumoto, Keiji Sugiyama, Takeshi Kajiwara, Hiroyuki Okuda, Naoki Aomatsu, Hisato Kawakami, Taito Esaki, Yukiya Narita, Hiroki Hara, Yu Sunakawa, Narikazu Boku, Toshikazu Moriwaki, Takako Eguchi Nakajima, and Kei Muro.
  • A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
    Tomohiro Nishina, Takuro Mizukami, Keiko Minashi, Hiroki Hara, Yusuke Amanuma、Naoki Takahashi、Akio Nakasha, Masaki Takahashi, Takako Eguchi Nakajima.
2021.03 第93回日本胃癌学会総会
  • Bi-weekly nab-paclitaxel and ramucirumab therapy for advanced gastric cancer: JACCRO GC-09 trial.
    Naoki Izawa, Mitsugu Kochi, Shigenori Kadowaki, Ryohei Kawabata, Takao Takahashi, Akihito Tsuji, Hiroki Hara, Masato Nakamura, Toshikazu Moriwaki, Yu Sunakawa, Wataru Ichikawa, and Masashi Fujii.
  • TAS-118 plus oxaliplatin as perioperative chemotherapy in gastric cancer (APOLLO-11)
    Takuro Mizukami, Daisuke Takahari, Atsuo Takahshima, Naoki Ishizuka, Manabu Ohashi, Hitoshi Katai, Shinya Mikami, Takeshi Sano, Narikazu Boku, Kensei Yamaguchi.

学会発表(国際学会)

2022年度
2022.06 ASCO Annual Meeting
  • Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
    Hiroyuki Arai, Yan Yang, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Zhang Wu, Alan P. Venook, Yu Sunakawa, Heinz-Josef Lenz.
  • Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
    Yoshinori Kagawa, Daisuke Kotani, Hideaki Bando, Naoki Takahashi, Tetsuya Hamaguchi, Akiyoshi Kanazawa, Takeshi Kato, Koji Ando, Hironaga Satake, Eiji Shinozaki, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Satoshi Yuki, Hiromichi Nakajima, Yoshiaki Nakamura, Masashi Wakabayashi, Hiroya Taniguchi, Takashi Ohta, Takayuki Yoshino.
  • “Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
    Satoshi Yuki, Yu Sunakawa, Kentaro Yamazaki, Hiromichi Shirasu, Hiroya Taniguchi, Toshiki Masuishi, Manabu Shiozawa, Hideaki Bando, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake, Atsuo Takashima, Yukiko Abe, Shogo Nomura, Takayuki Yoshino.
  • 2021年度
    2021.06 ASCO Annual Meeting
    • Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions.
      Alison M. Schram, Eileen Mary O’Reilly, Grainne M. O’Kane, Koichi Goto, Dong-Wan Kim, Cindy Neuzillet, Patricia Martin-Romano, Michaël Duruisseaux, Misako Nagasaka, Jordi Rodon, Benjamin Adam Weinberg, Kumiko Umemoto, Sai-Hong Ignatius Ou, Teresa Macarulla, Christelle De La Fouchardiere, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Alexander E. Drilon.
    • Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC); Update results from GI-SCREEN CRC Ukit study.
      Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Hironaga Satake, Akiyoshi Kanazawa, Masahiro Goto, Hideaki Bando, Hiroya Taniguchi, Yoshinaga Okugawa, Kentaro Yamazaki, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Chiharu Asano, Takayuki Yoshino.
    • The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
      HisatsuguOhori, TatsuroYamaguchi, Masato Matsuura, AtsujiroNishioka, AkitakaMakiyama, Shingo Noura, MitsuguKochi, Tamotsu Sagawa, Masahito Kotaka, YutaroKubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahito Takeuchi, WataruIchikawa and Masashi Fujii.
    • Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data.
      Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A. Moore, Ethan S. Sokol, Yu Sunakawa
    2021.06 MASCC
    • The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer.
      Hiroyuki Takeda, Shigenori Kadowaki, Takeshi Kajiwara, Keiko Minashi, Naoki Izawa, Kei Muro, Tomohiro Nishina, Shuichi Hironaka, Takeharu Yamanaka, Takako Eguchi Nakajima.
    2021.07 ESMO-GI
    • Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: the DELIVER trial (JACCRO GC-08).
      Yu Sunakawa, Ryo Matoba, Eisuke Inoue, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.
    • A multicenter phase Ⅱ trial of trifluridine/thipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody:the WJOG8916G trial.
      T. Masuishi, N. Izawa, N. Takahashi, H. Shoji, Y. Yamamoto, T. Matsumoto, K. Sugiyama, T. Kajiwara, K. Kawakami, N. Aomatsu, C. Kondoh, H. Kawakami, N. Takegawa, T. Esaki, Y. Narita, H. Hara, Y. Sunakawa, N. Boku, T. Moriwaki, M. Shimokawa, TE. Nakajima, K. Muro.
    • Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial.
      N. Takahashi, N. Izawa, K. Nishio, T. Masuishi, H. Shoji, Y. Yamamoto, T. Matsumoto, K. Sugiyama, T. Kajiwara, K. Kawakami, N. Aomatsu, H. Kawakami, T. Esaki, Y. Narita, H. Hara, Y. Horie, N. Boku, T. Moriwaki, K. Miura, M. Shimokawa, TE. Nakajima, K. Muro.
    2021.09 ESMO
    • Impact of plasma angiogenesis factors on the efficacy of 2nd-line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC); Early efficacy results from GI-SCREEN CRC Ukit study.
      Satoshi Yuki, Hiroya Taniguchi, Toshiki Masuishi, Manabu Shiozawa, Hideaki Bando, Kentaro Yamazaki, Tomohiro Nishina, Hisateru Yasui, Tadamichi Denda, Yu Sunakawa, Hironaga Satake, Kazuhiro Yoshida, Akiyoshi Kanazawa,Eiji Oki, Yoshinaga Okugawa, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Chiharu Asano, Takayuki Yoshino.
    • Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing.
      H. Yamamoto, R. Oikawa, H. Takeda, K. Umemoto, A. Doi, Y. Horie, T. Ogura, T. Mizukami, N. Izawa, J.A. Moore, E. Sokol, Y. Sunakawa.
    • Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED Trial.
      K. Shimomur, H. Minatogawa, T. Mashiko, H. Arioka, H. Iihara, M. Sugawara, N.Hida, K. Akiyama, S. Nawata, A. Tsuboya, K. Mishima, N. Izawa, T. Miyaji, K.Honda, Y. Inada, Y. Ohno, C. Katada, H. Morita, T. Yamaguchi, TE. Nakajima.
    2022.01 ASCO-GI
    • A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09).
      Takahisa Suzuki, Naoki Izawa, Ryohei Kawabata, Kazuhiro Nishikawa, Masazumi Takahashi, Masato Nakamura, Atsushi Ishiguro, Hiroo Katsuya, Jun Hihara, Dai Manaka, Yuji Negoro, Mizutomo Azuma, Akihito Tsuji, Mitsugu Kochi, Takao Takahashi, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa, Masashi Fujii.
    • Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).
      Yu Sunakawa, Ryo Matoba, Toshizo Takayama, Naoki Okumura, Naotoshi Sugimoto, Kou Miura, Satoshi Yuki, Yoshiaki Shindo, Hidekazu Kuramochi, Sho Sato, Takashi Ogura, Shinichi Kinami, Narutoshi Nagao, Shugo Ueda, Eisuke Inoue, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, Masashi Fujii.
    • Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).
      Hironaga Satake, Akihito Tsuji, Chihiro Tanaka, Takao Takahashi, Kunihiko Wakamura, Taichi Yoshida, Kohei Murata, Yoshiaki Shindo, Yasuhide Ishikawa, Ken Konishi, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.
    • Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.
      Hiroyuki Takeda, Hiroyuki Yamamoto, Ritsuko Oikawa, Kumiko Umemoto, Ayako Doi, Yoshiki Horie, Takuro Mizukami, Takashi Ogura, Naoki Izawa, Jay A. Moore, Ethan Sokol, Yu Sunakawa.
    2020年度
    2020.05 ASCO 2020 Virtual
    • A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).
      Masataka Yagisawa, Yoshiaki Nakamura, Takayuki Yoshino, Yoshito Komatsu, Shigenori Kadowaki, Kei Muro, Yu Sunakawa, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Satoshi Fujii, Hiromi Ono, Daiki Tomita, Noriko Fujishiro, Nami Hirano, Nozomu Fuse, Akihiro Sato, Gakuto Ogawa, Shogo Nomura, Hiroya Taniguchi.
    • Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: real-world data from a large observational/translational study, JACCRO GC-08 (DELIVER trial) .
      Ryohei Kawabata, Yasuhiro Sakamoto, Eisuke Inoue, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Hisato Kawakami, Ryo Matoba, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, Masashi Fujii, and Yu Sunakawa.
    • Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.
      Yoshiaki Nakamura, Hiroya Taniguchi, Hideaki Bando, Taito Esaki, Yoshito Komatsu, Ken Kato, Naoki Takahashi, Yoshinori Kagawa, Takeshi Kato, Tomohiro Nishina, Taroh Satoh, Eiji Oki, Yu Sunakawa, Manabu Shiozawa, Yoshiyuki Yamamoto, Hisato Kawakami, Tadamichi Denda, Atsushi Ohtsu, Takayuki Yoshino.
    • Phase II trial of adjuvant mFOLFOX6 after metastasectomy for pulmonary metastasis of colorectal cancer: WJOG5810G.
      Nozomu Machida, Takehiro Okumura, Junji Kishimoto, Narikazu Boku, Tomohiro Nishina, Koichi Suyama, Yasuhisa Ohde, Katsunori Shinozaki, Hideo Baba, Shinya Tokunaga, Hisato Kawakami, Takashi Tsuda, Masahito Kotaka, Hiroyuki Okuda, Hisateru Yasui, Tadamichi Denda, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro, Ichinosuke Hyodo.
    2020.05 92nd Annual Meeting of the Japanese Gastric Cancer Association
    • Feasibility of TAS-118+oxsliplation as perioperaive chemotherapy for gastric cancer.
      Takahari Daisuke, Takashima Atsuto, Nakajima Takako, Ohashi Manabu, Mikami Shinya, Ishizuka Naoki.
    2020.07 WCGC Virtual
    • Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer.
      Yu Sunakawa, Yasuhiro Sakamoto, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Naoki Hirabayashi, Atsushi Takeno, Hisato Kawakami, Ryo Matoba, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.
    2020.09 ESMO VIRTUAL CONGRESS
    • 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC).
      Naoki Izawa, Shigeki Ohta, Shigenori Kadowaki, Takeshi Kajiwara, Keiko Minashi, Yu Sunakawa, Kei Muro, Tomohiro Nishina, Shuichi Hironaka, Takeharu Yamanaka, Takako Eguchi Nakajima, Yutaka Kawakami.
    2020.11 ESMO ASIA
    • Anti-VEGF inhibitors and Renal Safety in Onco-Nephrology consortium -Urinary Protein/Creatinine ratio [VERSiON UP study].
      M. Nakamura, T. Funakoshi, S. Kataoka, T. Horimatsu, Y. Nishikawa, T. Matsubara, T. Mizukami, T. Goto, K. Tsuchihashi, E. Baba, T. Tsumura, Y. Mihara, T. Hamaguchi, M. Yanagita, M. Muto.
    2021.01 ASCO GI 2021
    • Efficacy of chemotherapy for patients with unresectable or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
      Yukio Yoshida, Akira Fukutomi, Makoto Ueno, Keita Mori, Kazuo Watanabe, Akihiro Ohba, Satoshi Kobayashi, Mitsuhiro Furuta, Akiko Tsujimoto, Masato Osaka, Naohiro Okano, Kei Yane, Kumiko Umemoto, Yasuyuki Kawamoto, Takeshi Terashima, Hidetaka Tsumura, Keitaro Doi, Kazuhiko Shioji, Akinori Asagi, Junji Furuse.
    • Feasibility study of TAS-118 plus oxaliplation as perioperative chemotherapy for patients with advanced gastric cancer(APOLLO-11).
      Takahari Daisuke, Ohashi Manabe, Takashima Atsuo, Mizukami Takuro, Ishizuka Naoki, Katai Hitoshi, Mikami Shinya, Wakatsuki Takeru, Chin Keisho, Ida Satoshi, Kumagai Koshi, Nunobe Souya, Iwasa Satoru, Ito Miki, Wada Takeyuki, Yamagata Yikinori, Ogura Takashi, Sano Takeshi, Boku Narikazu, Yamaguchi kensei.
    • Phase Ⅱ study of systemic chemotherapy with S-1 plus oxaliplation followed by surgery in patients with cT3-T4a and/or node-positive advanced adenocarcinoma of the esophagogastric junction;Primary endpoint results of the ESOX trial.
      Imamura Yu, Chin Keisho, Tsushima Takahito, Tsubosa Yasuhiro, Hara hiroki, Fukuda Takashi, Nomura Motoo, Tsunoda Shigeru, Ogata Takashi, Hayashi Tsutomu, Nabeya Yoshihiro, Minashi Keiko, Kuramochi Hidekazu, Hamano Mie, Doi Ayako, Mikami Shinya, Mine Shinji, Isizuka Naoki, Ichimura Takashi.
    • A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial.
      Ayako Doi, Kumiko Umemoto, Tomoyo Oguri, Hiroyuki Takeda, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Sungmok Jung, Byung Chul Kim, Yu Sunakawa.
    • A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
      Hiroki Hara, Takuro Mizukami, Keiko Minashi, Tomohiro Nishina, Naoki Takahashi, Yusuke Amanuma, Akio Nakasha, Masaki Takahashi, Takako Eguchi Nakajima.
    • Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08)
      Yu Sunakawa, Ryo Matoba, Eisuke Inoue, Yoshikazu Takahashi, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.

    論文業績(和文)

    2021年度

    《原著・総説・解説》

    1. 消化器癌;診断・治療のすべて
    • 化学療法, 44(6):608-614.
    • 伊澤直樹、砂川優
    2020年度

    《原著・総説・解説》

    1. 上部消化管がん治療State of the art
    • 腫瘍内科, 25(6)604-12.
    • 伊澤直樹、中島貴子
    2. 消化器がんの病態と治療
    • 消化器ナーシング, 2020年5月号.
    • 水上拓郎
    3. 胃がん一次治療HER2以外の分子標的薬の開発
    • オンコロジークリニカルガイド.
    • 水上拓郎
    4. ラムシルマブ、下痢
    • YORi-SOU がんナーシング, 2020.
    • 伊澤直樹、小倉孝氏
    5. 診断時からの緩和ケア―本当の意味
    • 医学のあゆみ ,274(8):655-659
    • 堀江良樹
    6. 口内炎、下痢・便秘、嘔吐・悪心、味覚障害
    • Clinical nursing Skills ひとりだちできる がん化学療法看 護 ,2021
    • 伊澤直樹
    7. 大腸癌三次治療以降
    • オンコロジークリニカルガイド 消化器癌化学療法改定5版 ,2021;5:280-287.
    • 伊澤直樹
    8. がん化学療法の薬はや調べノート2020・2021年版
    • オンコロジークリニカルガイド 消化器癌化学療法改定5版 ,2021;5:280-287.
    • 伊澤直樹
    9. パクラムニボ論文の英訳と監修
    • 消化器病の広場 ,2021;0(0):0-0.
    • 伊澤直樹、武田弘幸
    2019年度

    《原著・総説・解説》

    1. 腫瘍内科医に必要な緩和医療のポイント
    • 臨床腫瘍プラクティス, 15(3).
    • 土井綾子
    2. 肝機能障害への対応
    • がん免疫療法, 3(1):24-26,2019.
    • 新井裕之, 中島貴子
    3. 後方ライン治療におけるICのポイント
    • 大腸癌に対するレゴラフェニブ治療,80-84,2019.
    • 新井裕之, 中島貴子
    4. がん治療におけるPatient-Reported Outcome
    • 腫瘍内科,2019;25(1).78-83.
    • 土井綾子、堀江良樹、中島貴子
    5. 分子標的治療 消化器がんにおける分子標的治療薬
    • 消化器外科専門医の心得,2019;第1般.158-162.
    • 伊澤直樹、中島貴子

    論文業績(英文)

    《2022年度》

    《原著・総説・解説》

    1. APhase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
    • Anticancer Res, 42(5):2675-2681, 2022.
    • Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, Denda T, Takagane A, Watanabe T, Kotaka M, Nakamura M, Sunakawa Y, Takeuchi M, Ichikawa W, Fujii M.
    2. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.
    • Targeted Oncology, 17(3):343-353, 2022.
    • Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, Kato K, Hara H, Denda T, Yamamoto Y, Shiozawa M, Oki E, Okamoto W, Yoshino T, Eguchi Nakajima T.
    3. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
    • JCO Precis Oncol, Apr;6:e2100535., 2022.
    • Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, Kagawa Y, Denda T, Satoh T, Yamazaki K, Sunakawa Y, Kato T, Goto M, Yuki S, Nishina T, Oki E, Shinozaki E, Matsuhashi N, Takahashi N, Tsuji A, Ohtsubo K, Wakabayashi M, Ikeno T, Hata M, Odegaard JI, Yoshino T.
    4. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling.
    • J Natl Cancer Inst, 114(9):1279-1286, 2022.
    • Umemoto K, Yamamoto H, Oikawa R, Takeda H, Doi A, Horie Y, Arai H, Ogura T, Mizukami T, Izawa N, Moore JA, Sokol ES, Sunakawa Y.
    5. NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
    • J Cancer Res Clin Oncol, 148(10):2841-2854, 2022.
    • Kajiwara T, Nishina T, Nakasya A, Yamashita N, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Moriwaki T, Denda T, Ohtsubo K, Sunakawa Y, Horita Y, Kawakami H, Kato T, Satoh T, Ando K, Mizutani T, Yasui H, Goto M, Okuyama H, Yamazaki K, Yoshino T, Hyodo I.
    6. Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
    • Clin Colorectal Cancer, 21(3):259-266, 2022.
    • Hiroyuki Arai, Joshua Millstein, Yan Yang, Sebastian Stintzing, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, V3olker Heinemann, Heinz-Josef Lenz.
    7. fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing.
    • Bioinform Adv, 13;2(1):vbac047, 2022.
    • Joshua Millstein, Francesca Battaglin, Hiroyuki Arai, Wu Zhang, Priya Jayachandran, Shivani Soni, Aparna R Parikh, Christoph Mancao, Heinz-Josef Lenz.
    8. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
    • Eur J Cancer, 21;172:22-30, 2022.
    • Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Yan Yang, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Tianshu Liu, Volker Heinemann, Alfredo Falcone, Lin Shen, Joshua Millstein, Heinz-Josef Lenz.
    9. A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
    • ESMO Open, 2022.
    • Okamoto W, Sakai K, Makiyama A, Yamamoto Y, Shitara K, Denda T, Izawa N, Nakano Y, Nishina T, Esaki T, Hara H, MiuraY, Boku N, Yamazaki K, Hironaka S, Misumi T, Hyodo I, Muro K, Nishio K.
    《2021年度》

    《原著・総説・解説》

    1. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
    • Future Oncology, 17(19):2431-2438, 2021.
    • Takuro Mizukami, Tempei Miyaji, Yukiya Narita, Tomohiro Matsushima, Takashi Ogura, Hiromichi Miyagaki, Ryohei Kawabata, Yoshiki Horie, Takashi Kawaguchi, Kei Muro, Hiroki Hara, Takuhiro Yamaguchi& Takako E Nakajima.
    2. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
    • European Journal of Cancer, 150:133-142, 2021.
    • Hiroyuki Arai, Joshua Millstein, Fotios Loupakis, Sebastian Stintzing, Jingyuan Wang, rancesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Shannon M Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Heinz-Josef Lenz.
    3. Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cance.
    • Clin Cancer Res, 27(20)5619-5627, 2021.
    • Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin I Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino.
    4. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
    • Annals of Oncology, 32(7):906-916, 2021.
    • J Y Wang, J Xiu, Y Baca, H Arai, F Battaglin, N Kawanishi, S Soni, W Zhang, J Millstein, A F Shields, A Grothey, B A Weinberg, J L Marshall, E Lou, M Khushman, D P S Sohal, M J Hall, M Oberley, D Spetzler, L Shen, W M Korn, H J Lenz.
    5. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
    • Oncogene, 40:4894-4905, 2021.
    • Jingyuan Wang, Joanne Xiu, Yasmine Baca, Francesca Battaglin, Hiroyuki Arai, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Bodour Salhia, Richard M Goldberg, Philip A Philip, Andreas Seeber, Jimmy J Hwang, Anthony F Shields, John L Marshall, Igor Astsaturov, A Craig Lockhart, Zoran Gatalica, W Michael Korn, Heinz-Josef Lenz.
    6. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
    • Gastric Cancer.
    • Yoshikazu Takahashi, Yu Sunakawa, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yosuke Kito, Yusuke Akamaru, Masazumi Takahashi, Hiroshi Yabusaki, Jin Matsuyama, Akitaka Makiyama, Masahiro Tsuda, Takahisa Suzuki, Hisateru Yasui, Ryo Matoba, Hisato Kawakami, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa, Masashi Fujii.
    7. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
    • J Natl Cancer Inst, djab169.
    • Roberto Moretto, Andrew Elliott, Jian Zhang, Hiroyuki Arai, Marco Maria Germani, Veronica Conca, Joanne Xiu, Phillip Stafford, Matthew Oberley, Jim Abraham, David Spetzler, Daniele Rossini, Carlotta Antoniotti, John Marshall, Anthony Shields, Gilberto Lopes, Sara Lonardi, Filippo Pietrantonio, Gianluca Tomasello, Alessandro Passardi, Emiliano Tamburini, Daniele Santini, Giuseppe Aprile, Gianluca Masi, Alfredo Falcone, Heinz-Josef Lenz, Michael Korn, Chiara Cremolini.
    8. Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing.
    • Cancers (Basel), 13(19):4862, 2021.
    • Masahiro Kozuka, Francesca Battaglin, Priya Jayachandran, Jingyuan Wang, Hiroyuki Arai, Shivani Soni, Wu Zhang, Mitsuharu Hirai, Satoshi Matsusaka, Heinz-Josef Lenz.
    9. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
    • Cancer Medicine, 10(21):7673-7682, 2021.
    • Hiroyuki Arai, Eisuke Inoue, Kensei Yamaguchi, Narikazu Boku, Hiroki Hara, Tomohiro Nishina, Masahiro Tsuda, Kohei Shitara, Katsunori Shinozaki, Shinichiro Nakamura, Ichinosuke Hyodo, Kei Muro, Mitsuru Sasako, Masanori Terashima, Takako E Nakajima.
    10. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    • Br J Cancer.
    • Hiroyuki Arai, Yi Xiao, Joshua Millstein, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M Mumenthaler, Aparna R Parikh, Heinz-Josef Lenz.
    11. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer.
    • Future Oncology, 17(23):3101-3109, 2021.
    • Takuro Mizukami, Yongzhe Piao.
    12. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
    • Critical Reviews in Oncology/Hematology, 166:103465, 2021.
    • Kumiko Umemoto, Yu Sunakawa.
    13. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
    • Springer Nature, 41:260-267, 2021.
    • Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang-Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Davendra Sohal, Richard M Goldberg, Michael J Hall, Aaron J Scott, Mohd Khushman, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, Albert Craig Lockhart, Anthony Frank Shields, Jim P Abraham, Daniel Magee, Phillip Stafford, Jian Zhang, Alan P Venook, W Michael Korn, Heinz-Josef Lenz.
    14. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
    • JCO Precis Oncol, e2100383, 2022.
    • Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, Esaki T, Sunakawa Y, Ueno M, Shinozaki E, Matsuhashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K, Yoshino T.
    15. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.
    • ESMO Open, 7(2):100415, 2022.
    • N Izawa, H Shiokawa, R Onuki, K Hamaji, K Morikawa, H Saji, H Ohashi, S Kasugai, N Hayakawa, T Ohara, Y Sunakawa.
    16. A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701.
    • Eur J Cancer, 166:279-286, 2022.
    • Kazuma Kobayshi, Koichi Suyama, Hiroo Katsuya, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka, Kazunori Shibao, Satoshi Koga, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Eiji Oki, Hideo Baba, Masaki Mori.
    17. Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers.
    • Targeted Oncology, 17:177–185, 2022.
    • Hiroyuki Takeda, Kiyomi Imoto, Kumiko Umemoto, Ayako Doi, Hiroyuki Arai, Yoshiki Horie, Takuro Mizukami, Tomoyo Oguri, Takashi Ogura, Naoki Izawa, Hiroyuki Yamamoto, Yoshihisa Yamano & Yu Sunakawa.

    《症例報告》

    1. Detection of a pinhole-sized bronchoesophageal fistula under bronchoscopic autofluorescence imaging.
    • Thoracic Cancer, 12(13):2043-2045, 2021.
    • Kei Morikawa, Naoki Izawa, Hirotaka Kida, Hiroshi Handa, Takeo Inoue, Masamichi ineshita.
    2. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
    • BMC Cancer, 21(1):674, 2021.
    • Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, Yoshino T, Ohta T, Taniguchi H, Kagawa Y.
    《2020年度》

    《原著・総説・解説》

    1. Recent Developments of Systemic Chemotherapy for Gastric Cancer.
    • Cancers (Basel). 12(5):1100 , 2020.
    • Hiroyuki Arai, Takako Eguchi Nakajima.
    2. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
    • International Journal of Clinical Oncology. 25(10):1835-1843, 2020.
    • Naohiro Okano, Chigusa Morizane, Shogo Nomura, Hideaki Takahashi, Hidetaka Tsumura, Hironaga Satake, Nobumasa Mizuno, Kunihiro Tsuji, Kazuhiko Shioji, Akinori Asagi, Kohichiroh Yasui, Sho Kitagawa, Tomomi Kashiwada, Atsushi Ishiguro, Masashi Kanai, Makoto Ueno, Takashi Ogura, Satoshi Shimizu, Tobimatsu Kazutoshi, Masayo Motoya, Koji Nakashima, Masafumi Ikeda, Takuji Okusaka, Junji Furuse.
    3. Randomised Phase II Study of Panitumumab Plus Irinotecan Versus Cetuximab Plus Irinotecan in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G)
    • Eur J Cancer. 135:11-21, 2020.
    • Daisuke Sakai, Hiroya Taniguchi, Naotoshi Sugimoto, Takao Tamura, Tomohiro Nishina, Hiroki Hara, Taito Esaki, Tadamichi Denda, Takeshi Sakamoto, Hiroyuki Okuda, Taroh Satoh, Takahiro Tsushima, Akitaka Makiyama, Takashi Tsuda, Ayumu Hosokawa, Hidekazu Kuramochi, Shinya Tokunaga, Toshikazu Moriwaki, Hisateru Yasui, Hiroyasu Ishida, Akihito Tsuji, Satoshi Otsu, Hozumi Shimokawa, Eishi Baba, Mikio Sato, Shigemi Matsumoto, Yukinori Ozaki, Katsunori Shinozaki, Hiroshi Tamagawa, Masahiro Goto, Shigenori Kadowaki, Hirofumi Fujii, Yasuhiro Koh, Kentaro Yamazaki, Shuichi Hironaka, Junji Kishimoto, Narikazu Boku, Ichinosuke Hyodo, Kei Muro.
    4. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
    • Eur J Cancer. 38(17):1919-27, 2020.
    • Akitaka Makiyama , Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki, Keita Uchino, Hirofumi Yasui, Hiroshi Tsukuda, Kazuhiro Nishikawa, Hiroyasu Ishida, Takeharu Yamanaka , Kentaro Yamazaki , Shuichi Hironaka, Taito Esaki, Narikazu Boku, Ichinosuke Hyodo, Kei Muro.
    5. Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
    • Cancer Chemotherapy and Pharmacology. 86:277–284, 2020.
    • Yosuke Kito, Hironaga Satake, Hiroya Taniguchi, Takeshi Yamada, Yoshiki Horie, Taito Esaki, Tadamichi Denda, Hisateru Yasui, Naoki Izawa, Toshiki Masuishi, Toshikazu Moriwaki, Keita Mori, Kentaro Yamazaki.
    6. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
    • Investigational New Drugs. 38(2):410-418, 2020.
    • Takako Eguchi Nakajima, Narikazu Boku, Ayako Doi, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa.
    7. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer.
    • JCO presion oncology. 4(2020):898-911, 2020.
    • Yu Sunakawa, Masato Nakamura, Masahiro Ishizaki, Masato Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa, Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatsugu Ohori, Michio Nakamura, Fumiyo Maeda, Chihiro Komeno, Tomoko Sonezaki, Masahiro Takeuchi, Masashi Fujii, Takayuki Yoshino, Akihito Tsuji, and Wataru Ichikawa.
    8. Early tumor shrinkage and depth of response in the second-line treatment for KRAS exon2 wild-type metastatic colorectal cancer: An exploratory analysis of the randomized phase 2 trial comparing panitumumab and bevacizumab in combination with FOLFIRI (WJOG6210G).
    • Targeted Oncology. 2020(15):623-633, 2020.
    • Naoki Izawa, Kohei Shitara, Kimio Yonesaka, Takeharu Yamanaka, Takayuki Yoshino, Yu Sunakawa, Toshiki Masuishi, Tadamichi Denda, Kentaro Yamazaki, Toshikazu Moriwaki, Hiroyuki Okuda, Chihiro Kondoh, Tomohiro Nishina, Akitaka Makiyama, Hideo Baba, Hironori Yamaguchi, Masato Nakamura, Ichinosuke Hyodo, Kei Muro, Takako Eguchi Nakajima.
    9. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.
    • Cancers (Basel). 2(10):2947, 2020.
    • Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ.
    10. Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR).
    • J Cancer Sci Clin Ther. 4(4):499-510, 2020.
    • Hiroya Taniguchi, Yasuhiro Koh, Naotoshi Sugimono, Tomohiro Nishina, Takao Tamura, Hiroki Hara, Taito Esaki, Tadamichi Denda, Akitaka Makiyama, Aya Sakai, Hiroyuki Okuda, Naoki Izawa, Takayuki Ando, Kentaro Yamazaki, Shinya Tokunaga, Toshikazu Moriwaki, Akihito Tsuji, Hidekazu Kuramochi, Katsunori Shinozaki, Yukinori Ozaki, Hironori Yamaguchi, Hisateru Yasui, Satoshi Otsu, Mio Ikeda, Junji Kishimoto, Taroh Satoh, Daisuke Sakai, Kei Muro.
    11. Prospective evaluation and refinement of an S-1 dosage formula based on renal function for the clinical application.
    • Cancer Science. 111(2):751-759, 2020.
    • Takeuchi Masashi, Imamura Chiyo, Booka Eisuke, Takeuchi Hiroya, Mizukami Takuro, Kawakami Takeshi, Funakoshi Taro, Wakuda Kazushige, Aoki Yu, Hamamoto Yasuo, Kitago Minoru, Kawakubo Hirofumi, Boku Narikazu, Tanigawara Yusuke, Kitagawa Yuko.
    12. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer .
    • Hiroyuki Arai, Yi Xiao, Fotios Loupakis, Natsuko Kawanishi, Jingyuan Wang, Francesca Battaglin, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M Mumenthaler, Daniel J Weisenberger, Gangning Liang, Chiara Cremolini, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz.
    13. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
    • Cancer science. 112(1):314-322, 2020.
    • Hasegawa Hiroko, Taniguchi Hiroya, Nakamura Yoshiaki, Kato Takeshi, Fujii Satoshi, Ebi Hiromichi, Shiozawa Manabu, Yuki Satoshi, Masuishi Toshiiki, Kato Ken, Izawa Naoki, Moriwaki Toshikazu, Oki Eiji, Kagawa Yoshinori, Denda Tadamichi, Nishina Tomohiro, Tsuji Akihito, Hara Hiroki, Esaki Taito, Nishida Naohiro, Kawakami Hisato, Sakamoto Yasumasa, Miki Izumi, Okamoto Wataru, Yamazaki Kentaro, Yoshino Takayuki.
    14. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    • Eur J Cancer. 140:119-129, 2020.
    • Ryuma Tokunaga, Joanne Xiu, Richard M Goldberg, Philip A Philip, Andreas Seeber, Francesca Battaglin, Hiroyuki Arai, Jae Ho Lo, Madiha Naseem, Alberto Puccini, Martin D Berger, Shivani Soni, Wu Zhang, Sting Chen, Jimmy J Hwang, Anthony F Shields, John L Marshall, Hideo Baba, W Michael Korn, Heinz-Josef Lenz.
    15. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.
    • J Hepatobiliary Pancreat Sci. 28(1):1-25, 2020.
    • Masakazu Yamamoto, Masahiro Yoshida, Junji Furuse, Keiji Sano, Masayuki Ohtsuka, Shingo Yamashita. Toru Beppu, Yukio Iwashita, Keita Wada, Nakajima Eguchi Takako, Katsunori Sakamoto, Koichi Hayano, Yasuhisa Mori, Koji Asai, Ryusei Matsuyama, Teijiro Hirashita, Taizo Hibi, Nozomu Sakai, Tsutomu Tabata, Hisato Kawakami, Hiroyuki Takeda, Takuro Mizukami, Masato Ozaka, Makoto Ueno, Yoichi Naito, Naohiro Okano, Takayuki Ueno, Susumu Hijioka, Satoru Shikata, Tomohiko Ukai, Steven Strasberg, Michael G. Sarr, Palepu Jagannath, Tsann‐Long Hwang, Ho‐Seong Han, Yoo‐Seok Yoon, Hee Jung Wang, Shao‐Ciao Luo, Rene Adam, Mariano Gimenez, Olivier Scatton, Do‐Youn Oh, Tadahiro Takada.
    16. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    • Clin Cancer Res. 27(4):1029-1036, 2020.
    • Takako Eguchi Nakajima, Shigenori Kadowaki, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Yuichiro Hayashi, Naoki Izawa, Kei Muro, Shuichi Hironaka, Takeshi Kajiwara, Yutaka Kawakami.
    17. Molecular characterization of appendiceal goblet cell carcinoid.
    • Molecular Cancer Therapeutics. 19(12):2634-2640, 2020.
    • Hiroyuki Arai, Yasmine Baca, Francesca Battaglin, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Joshua Millstein, Curtis Johnston, Richard M Goldberg, Philip A Philip, Andreas Seeber, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, John L Marshall, W Michael Korn, Heinz-Josef Lenz.
    18. RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC.
    • Molecular Cancer Therapeutics. 20(6):1153-1160, 2020.
    • Hiroyuki Arai, Shu Cao, Francesca Battaglin, Jingyuan Wang, Natsuko Kawanishi, Ryuma Tokunaga, Fotios Loupakis, Sebastian Stintzing, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz.
    19. Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
    • Int J Clin Oncol. 26(2):355-363, 2020.
    • Hiroyuki Arai, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Takako Eguchi Nakajima.
    20. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.
    • Clinical Cancer Research. , 2021.
    • Hiroyuki Arai, Andrew Elliott, Joanne Xiu, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Davendra Sohal, Richard M. Goldberg, Michael J. Hall, Aaron J. Scott, Moh’d Khushman, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, John L. Marshall, Albert C. Lockhart, Phillip Stafford, Jian Zhang, Roberto Moretto, Chiara Cremolini, W. Michael Korn and Heinz-Josef Lenz.
    21. Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives.
    • Front. Oncol. 4:0-0, 2021.
    • Hiroyuki Takeda, Yu Sunakawa.

    《症例報告》

    1. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report.
    • World Journal of Gastrointestinal Oncology ,12(11):1364-1371, 2020
    • Ayako Doi, Hiroyuki Takeda, Kumiko Umemoto, Ryosuke Oumi, Shinji Wada, Shingo Hamaguchi, Hidefumi Mimura, Hiroyuki Arai, Yoshiki Horie, Takuro Mizukami, Naoki Izawa, Takashi Ogura, Takako Eguchi Nakajima, Yu Sunakawa.

    《その他》

    1. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
    • Future Oncol. 17(8):0-0, 2020
    • Narita Y, Shoji H, Kawai S, Mizukami T, Nakamura M, Moriwaki T, Yamanaka T, Sunakawa Y, Kawakami H, Nishina T, Misumi T, Muro K.
    2. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
    • BMJ Open. 10(12):e041737, 2020
    • Hiroko Minatogawa, Naoki Izawa, Takashi Kawaguchi, Tempei Miyaji, Kazuhiro Shimomura, Honda Kazunori, Hirotoshi Iihara, Yasushi Ohno, Yusuke Inada, Hitoshi Arioka, Hajime Morita, Naoya Hida, Mitsuhiro Sugawara, Chikatoshi Katada, Shuichi Nawata, Hiroo Ishida, Ayako Tsuboya, Takashi Tsuda, Takuhiro Yamaguchi, Takako Eguchi Nakajima.

    臨床腫瘍学業績 2014年度~2019年度

PAGE TOP